Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients
Georg Pfeiler(Medical University of Vienna), Michael Seifert(Zimmer Biomet (Germany)), A. Fink-Retter(Mayo Clinic), E. Kubista(University of Vienna), Thomas Geisendorfer(Seibersdorf Laboratories (Austria)), Christian Glatz(Medical University of Vienna), Robert Königsberg(Kaiser-Franz-Josef-Spital), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 61
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403